Results 91 to 100 of about 34,274 (165)
Update on the use of memantine in Alzheimer’s disease
Neuropsychiatric Disease and Treatment, 2009 Robert J van MarumGeriatric Department, University Medical Center Utrecht, Utrecht, The NetherlandsAbstract: Memantine is a low to moderate affinity N-methyl-D-aspartate receptor (NMDAR) antagonist.
Robert J van Marum
doaj
Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy [PDF]
, 2013 Introduction: Memantine and cholinesterase inhibitors potentially offer additional benefits in Alzheimer's disease (AD) when used together. This study assessed the efficacy and safety of combination treatment with memantine added to stable donepezil in ...
Atri, Alireza +5 more
core +1 more source
Alzheimer's Disease in Africa: A Scoping Review Protocol
Health Science Reports, Volume 9, Issue 4, April 2026.ABSTRACT Background and Aims The global burden of Alzheimer's disease (AD) is set to increase in the next three decades particularly because of the global increase in life expectancy. The state of AD in Africa is a cause for concern because the continent's rapid population growth and demographic transition will be major contributors to AD's increased ...
Jonathan Ayeyi Nuamah +6 more
wiley +1 more source
The competitive NMDA antagonist CPP protects substantia nigra neurons from MPTP-induced degeneration in primates [PDF]
, 1993 Degeneration of nigrostriatal dopaminergic neurons is the primary histopathological feature of Parkinson's disease. The neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induces a neurological syndrome in man and non-human primates very ...
Burg, M. +7 more
core +1 more source
Cancer Neuroscience: Innovative Conception and Emerging Strategy of Therapy
MedComm, Volume 7, Issue 4, April 2026.In this review, we summarize nerve–cancer interactions and conclude two additional interactions, “perineural invasion” and “neuro‐microbic‐oncology.” Emphasizing the important role of nerves in tumor progression. The nervous system also contributes to the development of cancer comorbidities such as cancer depression and cognitive dysfunction.
Ting Wang +5 more
wiley +1 more source
Neuropsychiatric Disease and Treatment, 2018 Taro Kishi,1,* Shinji Matsunaga,1,2,* Nakao Iwata1 1Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi 470-1192, Japan; 2Department of Geriatrics and Cognitive Disorders, Fujita Health University School of Medicine ...
Kishi T, Matsunaga S, Iwata N
doaj
Journal of Neurochemistry, Volume 170, Issue 4, April 2026.Brain organoids and assembloids derived from human induced pluripotent stem cells (hiPSCs) represent a striking advance in biomedical research. These technologies allow a more accurate mimicry of the three‐dimensional cellular environment in vitro, enabling detailed investigations of Alzheimer's disease (AD) pathological features, such as β‐amyloid ...
Esther Marques Alves Maciel +3 more
wiley +1 more source
Neuroprotective effects of minocycline on double-stranded RNA-induced neurotoxicity in cultured cortical neurons [PDF]
, 2012 1. Minocycline, memantine,and glycoconjugate were assessed for their ability to protect cultured primary cortical neurons against double-stranded RNA-induced neurotoxicity. 2.
Chang, RCC +6 more
core
Memantine inhibits 6-OHDA-induced apoptosis PC12 cells via the Nurr77 and caspase pathway
Asian Pacific Journal of Tropical Medicine, 2019 Objective: To investigate the effect of memantine on Parkinson’s disease cell models. Methods: Parkinson’s disease cell models were established using PC12 cells incubated with 6-hydroxydopamine (6-OHDA).
Wei Wu +5 more
doaj +1 more source
Clinical Interventions in Aging, 2009 Stuart J Thomas, George T GrossbergDepartment of Neurology and Psychiatry, Saint Louis University School of Medicine, St. Louis, MO, USAAbstract: Memantine is an uncompetitive N-methyl-D-aspartate receptor antagonist with moderate affinity. Its mechanism
Stuart J Thomas, George T Grossberg
doaj